成釉细胞瘤中MMP-2的表达及RNA干扰的抑制作用

目的：研究MMP-2存成釉细胞瘤中的表达和RNA干扰对成釉细胞瘤细胞中MMP-2基因的沉默效应。方法：培养成釉细胞瘤细胞，应用免疫组织化学方法检测成釉细胞瘤中MMP-2的表达；体外构建MMP-2靶向siRNA质粒表达载体，将siRNA质粘表达载体转染原代培养的成釉细胞瘤细胞，激光共聚焦显微镜检测siRNA质粒表达载体的转染效率，RT-PCR检测成釉细胞瘤细胞中MMP-2 mRNA的改变，明胶酶谱法检测MMP-2的变化．应用SPSSI 1．0统计软件中的t检验对结果进行统计学分析。结果：成釉细胞瘤中MMP-2呈阳性表达．siRNA质粒表达载体对原代培养的成釉细胞瘤细胞的转染半为41.8％；转染后，成釉细胞瘤细胞的MMP-2 mRNA表达水平显著降低，酶原性MMP-2和活性MMP-2显著减少，P〈0．05结论：体外构建的MMP-2靶向siRNA质粒表达载体可以转染体外培养的成釉细胞瘤细胞，并导致MMP-2基因沉默。     

成釉细胞瘤MMP-2、TIMP-2、MT1-MMP mRNA的表达和意义

目的　探讨MMP 2、TIMP 2、MT1 MMP与成釉细胞瘤局部侵袭特性的生物学关系。方法　采用RT PCR方法检测基质金属蛋白酶及其抑制剂和激活剂MMP 2、TIMP 2、MT1 MMP在成釉细胞瘤的表达及含量。结果　在成釉细胞瘤组织中 ,MMP 2、MT1 MMP、TIMP 2的mRNA均表达 ,且表达水平均显著高于正常牙囊组织 ,复发及实性成釉细胞瘤的TIMP 2、MT1 MMP相对含量均显著高于原发和囊性成釉细胞瘤。结论　在成釉细胞瘤组织中 ,MMP 2、MT1 MMP、TIMP 2转录水平的增高可能与其侵袭特性有关 ,MT1 MMP/TIMP 2表达水平可能与其侵袭能力有关。     

负向调控基质金属蛋白酶-2的表达抑制成釉细胞瘤的侵袭性

目的探讨基质金属蛋白酶-2（MMP-2）靶向小干扰RNA（siRNA）对成釉细胞瘤（AM）细胞MMP-2基因的负向调控作用及对AM侵袭性的抑制作用。方法培养成釉细胞瘤细胞，应用免疫荧光法检测成釉细胞瘤中MMP-2的表达；体外构建MMP-2靶向siRNA质粒表达载体，并转染成釉细胞瘤细胞．激光共聚焦显微镜检测siRNA质粒表达载体的转染效果，流式细胞仪检测转染效率．逆转录聚合酶链反应检测MMP-2mRNA的改变，免疫印迹法检测细胞MMP-2蛋白表达．侵袭小室微侵袭分析检测细胞的侵袭性，对统计结果进行方差分析。结果成釉细胞瘤中MMP-2呈阳性表达，siRNA质粒表达载体对成釉细胞瘤细胞的转染率为63、6％；转染后，成釉细胞瘤细胞的MMP-2mRNA表达减少69．3％，MMP-2蛋白表达减少64.2％，P〈0．05，细胞的侵袭抑制率为61．2％。结论MMP-2靶向siRNA表达质粒成功转染成釉细胞瘤细胞并沉默MMP-2基因，MMP-2与细胞的侵袭性密切相关。     

成釉细胞瘤中基质金属蛋白酶MMP-2的表达及意义

:目的　探讨成釉细胞瘤局部侵袭性生长的生物学机制。方法　免疫组化 S- P法检测基质金属蛋白酶MMP- 2在成釉细胞瘤中的表达和分布。结果　成釉细胞瘤中 MMP- 2阳性染色位于肿瘤外周柱状细胞的胞浆中 ,中心星网状细胞未见表达 ;角化囊肿和含牙囊肿的上皮细胞中均未见 MMP- 2的阳性表达。结论　成釉细胞瘤细胞产生的 MMP- 2 ,导致基底膜成分 型胶原降解 ,破坏基底膜的完整性 ,这可能是成釉细胞瘤局部侵袭的机制之一。     

基质金属蛋白酶-2活性与成釉细胞瘤侵袭力的关系

目的：探讨基质金属蛋白酶-2（matrix metalloproteinase-2，MMP-2）活性与成釉细胞瘤体内、外侵袭力的关系。方法：通过MMP-2活性抑制剂R031—9790降低MMP-2活性进行干预处理，采用成釉细胞瘤细胞原代培养、瘤组织块裸鼠肾包膜下移植、MTT、Western印迹、体外侵袭试验、组织学和免疫组织化学等方法，观察MMP-2活性与成釉细胞瘤体内、外侵袭的关系。采用SPSS10．0统计软件包对上述数据进行χ^2检验和单因素方差分析。结果：R031-9790各处理组和对照组的生长曲线无显著差异（P〉0．05）。R031-9790对成釉细胞瘤细胞的体内、外侵袭均有显著的抑制作用（P〈0．01）。并可增加Ⅳ型胶原在瘤组织的阳性表达，减少E-钙黏素在瘤组织的异常表达，同时在体内、外均不影响成釉细胞瘤细胞MMP-2的表达。结论：MMP-2活性与成釉细胞瘤的侵袭直接相关；R031-9790可通过降低MMP-2活性而抑制成釉细胞瘤的侵袭；活性MMP-2可能通过调节Ⅳ型胶原及E-钙黏素的表达。影响成釉细胞瘤的侵袭。     

过表达RECK基因对成釉细胞瘤hTERT＋_AM永生化细胞株MMPs表达及侵袭能力的影响

目的：观察转染RECK基因对人成釉细胞瘤（ameloblastoma,AM）细胞株hTERT-AM的MMPs表达及细胞侵袭力的影响。方法：利用RECK基因慢病毒载体Lenti—RECK—eGFP／puro转染hTERTAM细胞株．Puro筛选和镜下挑单克隆纯化细胞。CCK8检测细胞活性,Transwell实验检测细胞迁移、侵袭能力,qRT—PCR检测细胞中RECK的mRNA的表达情况。Western蛋白印迹检测细胞中RECK、MMP2、MMP9的表达情况。采用SPSS13．0软件包对数据进行统计学分析。结果：转染RECK基因后,hTERT~AM细胞中RECK的mRNA和蛋白的表达均显著增高（P均〈0．01）,细胞活性无显著变化（P均〉0．05）,细胞迁移、侵袭能力均显著下降（P均〈0．01）,MMP2、MMP9蛋白表达均显著下降（P均〈0．05）。结论：RECK基因参与人成釉细胞瘤局部侵袭的调节,过表达RECK基因后,MMP2、MMP9下调,抑制AM细胞迁移和侵袭。RECK有望成为人成釉细胞瘤侵袭防治的新靶点。     

茶多酚对脂多糖介导下人牙周膜成纤维细胞 MMP-1、MMP-2表达的影响

目的：观察茶多酚（TP）在脂多糖（LPS）介导下对人牙周膜成纤维细胞（HPDLCs）MMP-1、MMP-2表达的影响。方法：体外培养 HPDLCs,在培养液中添加 TP（200μg/ml）作用于脂多糖（100μg/ml）介导的 HPDLCs,培养24、48、72 h,ELISA法检测 HPDLCs 分泌 MMP-1和 MMP-2的量。荧光实时定量 PCR 法检测 HPDLCs 中 MMP-1和 MMP-2 mRNA 的表达。结果：在 LPS 介导下 HPDLCs MMP-1和 MMP-2分泌量和基因表达升高,TP 可抑制 LPS 介导下 HPDLCs MMP-1和 MMP-2表达。结论：TP 可抑制 LPS 介导的人牙周膜细胞的胶原降解。     

基质金属蛋白酶MMP-2在龋病发展过程中的表达研究

目的：观察基质金属蛋白酶MMP-2在健康及不同程度龋损牙齿牙髓中的表达，初步研究MMP-2与龋病发展的关系。方法：以健康、浅龋和深龋牙齿中牙髓组织为研究对象，利用免疫组化、RT—PCR、实时荧光定量PCR和Western印迹检测MMP-2在其中的表达差异。采用单因素方差进行统计学分析。结果：组织标本免疫组化显示MMP-2在健康组和浅龋组中呈弱阳性表达，在深龋组中则表达强阳性。在健康组中仅表达于成牙本质细胞中，而在龋病组中牙髓细胞亦有表达。实时荧光定量PCR和Western印迹均检测到MMP-2在深龋组中表达明显高于其他两组，健康组和浅龋组表达无明显差异。结论：MMP-2的表达部位和强度与龋病的进展相关。     

MMP-2靶向siRNA对成釉细胞瘤裸鼠移植瘤的抑制作用

目的:构建裸鼠皮下人成釉细胞瘤移植瘤模型,研究MMP-2靶向siRNA对成釉细胞瘤侵袭性的抑制作用。方法:取新鲜成釉细胞瘤组织标本,剪切成1～2mm3组织小块,接种于裸鼠前肢根部的背侧皮下。实验分为3组:空白对照组不加任何处理因素;脂质体组注射脂质体混合物;siRNA组注射MMP-2靶向siRNA表达质粒混合物。组织块接种后第2周末开始施加处理因素,记录移植瘤体积和实验终止时的肿瘤重量。采用SPSS10.0统计软件包对数据进行t检验,并对移植瘤进行组织病理学分析。结果:所有移植瘤均成活,病理证实移植瘤为成釉细胞瘤,siRNA组和对照组之间肿瘤的体积有显著性差异,P<0.05。结论:裸鼠皮下接种成釉细胞瘤组织块构建成釉细胞瘤移植瘤动物模型是可行的,MMP-2靶向siRNA可在体内抑制成釉细胞瘤的侵袭性和生长。     

基质金属蛋白酶与Ⅳ型胶原在成釉细胞瘤的表达

目的探讨基质金属蛋白酶和Ⅳ型胶原与成釉细胞瘤复发、侵袭的关系。方法采用免疫组织化学LABC方法检测28例成釉细胞瘤组织中MMP-2、TIMP-2和Ⅳ型胶原的表达,并用RT-PCR方法检测MMP-2、TIMP-2和MT1-MMP在20例成釉细胞瘤的表达。结果MMP-2、TIMP-2和Ⅳ型胶原蛋白在成釉细胞瘤的阳性表达率分别为92.9%、75.0%和42.9%,Ⅳ型胶原阳性着色部位均位于基底膜及部分肿瘤细胞的胞质,MMP-2和TIMP-2阳性着色部位均位于细胞质,分布于瘤组织各层;复发性成釉细胞瘤Ⅳ型胶原的阳性表达率明显低于原发性成釉细胞瘤(P<0.01)。MMP-2、MT1-MMP、TIMP-2的mRNA在成釉细胞瘤组织中均有表达,复发性成釉细胞瘤的TIMP-2、MT1-MMP相对含量均显著高于原发性成釉细胞瘤(P<0.01)。结论基质金属蛋白酶MT1-MMP表达增加和Ⅳ型胶原在基底膜表达缺失与成釉细胞瘤的复发密切相关,MMP-2活性增加和基底膜Ⅳ型胶原降解增多可能是成釉细胞瘤局部侵袭的机制之一。     

Matrix Metalloproteinase-9 (MMP-9) Expression in Different Subtypes of Ameloblastoma

Background

Ameloblastoma is a common benign odontogenic tumor of the jaw with a local invasive and highly destructive behavior and can develop in any age, with peak prevalence in 3rd–4th decade. Ameloblastoma can be divided into six histological types: follicular, plexiform, acanthomatous, desmoplastic, granular, and basal cell. Matrix metalloproteinase-9 (MMP-9) (92-kD gelatinase/type IV collagenases = gelatinase B) is involved in bone resorption by degradation of extracellular matrix and osteoclasts recruitment. Recent studies have found that MMP-9 is expressed by ameloblastoma and has a role in ameloblastoma local invasiveness.

Objective

To analyze MMP-9 expression between different histological types of ameloblastoma.

Material and Method

Forty samples of ameloblastoma were collected through consecutive sampling and the MMP-9 expression was detected using immunohistochemistry.

Result

All samples showed positive MMP-9 expression with moderate to strong intensity. 82.4 % plexiform type and 83.3 % mixed type have strong immunoexpression, significantly different with follicular type with only 36.4 % (P < 0.05).

Conclusion

Ameloblastoma plexiform and mixed type have higher MMP-9 expression than ameloblastoma follicular type. Different MMP-9 expression may contribute in different ameloblastoma biological behavior.     

The role of RANKL and MMP‐9 in the bone resorption caused by ameloblastoma

J Oral Pathol Med (2010) 39 : 592–598 Background: Ameloblastoma, a common odontogenic tumor located in jaws, generally leads to severe damage to patient’s complexion and masticatory function. To expand in jaws, ameloblastoma must have a mechanism of resorbing the surrounding bone. Our objective was to explore the bone‐resorption mechanism of ameloblastoma by observing the role of Receptor activator of nuclear factor kappa B ligand (RANKL) and matrix metalloproteinase‐9 (MMP‐9) in the bone‐resorption process. Methods: In the study, the expression of RANKL and MMP‐9 in ameloblastoma was detected using immunohistochemistry (IHC) and RT‐PCR. Then, co‐culture system of ameloblastoma cells and bone marrow cells from neonatal rabbit was erected to observe the potential of ameloblastoma cells to induce osteoclastogenesis. Finally, the induced osteoclasts were used for in vitro bone‐resorption assay. In the co‐culture system and the bone‐resorption assay, the selective inhibitor of RANKL and MMP‐9, osteoprotegerin (OPG) and tissue inhibitor of metalloproteinase‐1 (TIMP‐1) were, respectively, used for observing the role of RANKL and MMP‐9. Results: The expression of RANKL and MMP‐9 in ameloblastoma was confirmed. Ameloblastoma cells were found to induce bone marrow cells from neonatal rabbit differentiate into osteoclasts with bone‐resorption activity. In addition, OPG was found to, respectively, have markedly inhibitory effect on osteoclastogenesis (P < 0.01), and slightly inhibitory action on bone resorption (P < 0.05). Conclusions: Ameloblastoma cells had the potential to induce osteoclastogenesis. Moreover, RANKL played an essential role in the in vitro osteoclast formation and bone resorption induced by ameloblastoma cells.     

白细胞介素-6对破骨细胞骨吸收效应及MMP-3表达影响的实验研究

目的：观察不同浓度IL－6对破骨细胞骨吸收的剂量效应及对破骨细胞基质金属蛋白酶－3表达的影响，以期进一步阐明IL－6介导基质金属蛋白酶在破骨细胞性骨吸收中的病理机制。方法：采用体外破骨细胞溶骨模型，通过原子吸收分光光度仪及免疫组化染色技术检测不同浓度IL－6对破骨细胞溶骨活性及其质金属蛋白酶－3表达的影响。结果：当IL－6＞10U／ml时，培养上清中Ca^2 浓度显著增加，牙本质片上骨吸收陷窝数目明显增多；当IL－6浓度为100U／ml、500U／ml时破骨细胞基质金属蛋白酶－3表达的阳性信号显著增强。结论：在IL－6作用下，破骨细胞表达基质金属蛋白酶－3。IL－6对破骨细胞具有激活作用，低浓度主要诱导破骨细胞形成，较高浓度刺激破骨细胞的溶骨活性。     

MAPK、MMP-2和MMP-9在唾液腺腺样囊性癌中的表达及临床意义

目的:研究人唾液腺腺样囊性癌组织中MAPK(p-ERK1/2、p-P38及p-JNK)、MMP-2和MMP-9的表达情况,探讨其与临床病理特征的关系.方法:应用免疫组织化学SP法检测27例腺样囊性癌组织标本(癌组)和15例正常唾液腺组织标本(对照组)中p-ERK1/2、P-P38、p-JNK、MMP-2和MMP-9的表达情况.采用SPSS17.0软件包对数据进行统计学分析.结果:p-ERK1/2、p-P38、p-JNK、MMP-2和MMP-9在腺样囊性癌组中的阳性表达率(分别为81.48%、88.89%、70.37%、81.49%和77.78%)均显著高于在正常唾液腺对照组中的阳性表达率(分别为20%、26.67%、26.67%、26.67%和26.67%),差异有统计学意义(分别为P<0,01、P<0.01、P<0.05、P<0.01和P<0.01).腺样囊性癌组织中p-ERK1/2、p-P38、MMP-2和MMP-9在Ⅲ～Ⅳ期组的阳性表达率(分别为88.89%、100%、94.44%和94.44%)显著高于Ⅰ一Ⅱ期组(分别为44.44%、66.67%、55.56%和44.44%),差异有统计学意义(分别为P<0.01、P<0.01、P<0.01和P<0.05),但p-JNK的表达与临床分期无统计学关系(P>0.05);p-ERK1/2、p-P38、p-JNK、MMP-2和MMP-9的表达与患者的性别、年龄、原发肿瘤部位、病理分型以及有无神经侵袭、复发和转移亦均无相关性(均为P>0.05);p-ERK1/2、P-P38、p-JNK与MMP-2和MMP-9的表达分别呈显著正相关(分别为r=0.786,P<0.001;r=0.796,P<0.001;r=0.824,P<0.001和r=0.768,P<0.001;r=0.581,P<0.01;r=0.604,P<0.01).结论:P-ERK1/2、p-P38、p-JNK、MMP-2和MMP-9的高表达与腺样囊性癌的临床分期及进展密切相关.MAPK/MMPs通路可能参与腺样囊性癌的发生、发展、侵袭及转移过程.     

正畸静压力通过p38MAPK调控牙周膜细胞MMP-2和MMP-9的表达

目的:研究持续性正畸静压力对牙周膜细胞(PDLCs)表达MMP-2和MMP-9的调控及其有关的调控通路。方法:体外培养PDLCs,取4~7代的PDLCs,随机分成5组,分别施加0、2 g/cm²(24 h)、2 g/cm²(48 h)、4 g/cm²(24 h)、4 g/cm²(48 h)的持续静压力,对细胞形态及骨架F-actin进行检测,通过Western blot观察持续静压力对MMP-2、MMP-8、MMP-9的表达的影响。研究相关MAPK通路包括JNK、ERK、p38MAPK在静压力引起MMPs表达变化中的作用。分组添加p38MAPK阻断剂SB203580,分别通过Western blot和免疫荧光观察p38MAPK通路的作用。结果:在不同的持续静压力下,PDLCs形态未见明显变化,F-actin染色显示细胞骨架未有明显区别。Western blot显示静压力对MMP-8表达未见明显影响,MMP-2和MMP-9的表达明显上调。且这种上调作用与p38MAPK通路有关,与JNK和ERK通路无关。结论:持续静压力调控PDLCs MMP-2和MMP-9的表达,这种调控通过p38MAPK途径产生作用,与JNK和ERK通路无关。     

罗格列酮对牙周炎大鼠牙龈脂联素受体表达的影响

目的:探讨罗格列酮(ROS)对牙周炎大鼠牙龈脂联素受体1(AdipoRl) mRNA、脂联素受体2(AdipoR2) mRNA和TNF-α等炎症因子表达的影响及在牙周炎中对牙槽骨保护的潜能.方法:50只SD大鼠随机分为5组(n=10),大鼠不干预处理作为空白对照,40只大鼠用于制作牙周炎模型后分别用蒸馏水(牙周炎组)、1、3、10 mg/kg ROS(低、中、高剂量组)灌胃1次/d,持续4周.然后取样,RT-PCR测定牙龈组织AdipoR1和AdipoR2 mRNA表达水平,ELISA测牙龈组织TNF-α、MMP-9和血浆脂联素浓度,标准化的数码摄影测量釉牙骨质界到牙槽骨嵴顶(CEJ-A)距离.结果:牙周炎组和空白对照组相比,牙龈组织AdipoR1和AdipoR2的mRNA表达水平显著降低(P＜0.01),血浆脂联素水平无差异(P＞0.05),TNF-α和MMP-9浓度显著上升(P＜0.01).和牙周炎组相比,低、中、高剂量治疗组牙龈组织AdipoRl mRNA表达均升高(P＜0.05),TNF-α浓度显著降低(P＜0.01);中、高剂量治疗组牙龈组织AdipoR2 mRNA表达显著升高(P＜0.01),MMP-9浓度显著降低(P＜0.01),血浆脂联素浓度升高(P＜0.05),牙槽骨吸收量显著降低(P＜0.01).结论:ROS可能通过上调牙龈组织中AdipoR1和AdipoR2 mRNA表达水平,降低TNF-α、MMP-9浓度,缓解牙周组织炎症,降低牙槽骨吸收.     

The effect of matrix metalloproteinase-9 on the differentiation into osteoclast cells on RAW264 cells

Matrix metalloproteinases (MMPs) break down the extracellular matrix (ECM) and are important proteins for bone remodeling. Here, to clarify relationships between MMPs and mechanisms of osteoclast differentiation, we used MMP inhibitor, GM6001, to investigate osteoclast differentiation engage to receptor activator of nuclear factor κB ligand (RANKL)/receptor activator of nuclear factor κB (RANK) stimulation using the RAW264 osteoclast precursor cell line. Also, since differentiation of RAW264 due to RANKL/RANK stimulation is dependent on p38 mitogen-activated protein kinase (p38 MAPK), we investigated expression of MMP-9 and osteocyte differentiation of RAW264 due to RANKL stimulation using SB203580, a p38 MAPK inhibitor. After confirming that GM6001 did not significantly affect cellular proliferation of the cell line, RAW264 was cultured with GM6001 and RANKL. GM6001 suppressed RANKL stimulation-induced tartrate-resistant acid phosphatase (TRAP)-positive polynuclear osteoclasts in a dose-dependent manner, and RANKL increased expression of MMP-9 in a dose-dependent manner. SB203580 also suppressed differentiation into TRAP-positive multinucleated osteocytes in a dose-dependent manner and blocked expression of MMP-9. These findings suggest that differentiation of osteoclasts by RANKL stimulation involves expression of MMP-9, which in turn involves p38 MAPK.     

Matrix metalloproteinase-9 regulates graft bone resorption

OBJECTIVE: To explore the relationship between bone resorption and matrix metalloproteinase-9 (MMP-9) expression in autogenous and allogenic bone grafts. MATERIALS AND METHODS: A total of 18 critical-size (10 x 15 mm) defects were created in rabbit mandibles bilaterally. Three groups of six defects each were grafted with autogenous endochondral (EC) bone, autogenous intramembranous (IM) bone, and allogenic IM bone. Three months later, the defects were retrieved for quantitative analysis on the basis of histology, immunohistochemistry, and in situ hybridization. RESULTS: A close relationship existed between MMP-9 expression and graft bone resorption. The parallel between MMP-9 expression and graft bone resorption suggested that bone resorption was accomplished in part by increased MMP-9 production evident in preosteoclasts and osteoclasts. CONCLUSIONS: MMP-9 plays an important role in graft bone resorption. Autogenous EC bone grafts express higher levels of MMP-9 leading to more resorption than autogenous or allogenic IM bone grafts.